Interim FDG-PET/CT Is an Independent Predictor of Overall Survival and Progression Free Survival in a Real-Life Cohort

Introduction: The prognostic value of interim FDG-PET/CT (iPET) in classic Hodgkin lymphoma (cHL) was demonstrated in several clinical trials. Although in last decade the PET/CT has been cHL gold standard for the staging at diagnosis and final response evaluation, the introduction of an early interi...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2019-11, Vol.134 (Supplement_1), p.1566-1566
Main Authors: Roque, Adriana, Neves, Dulcelena, Afonso, Maria Carolina, Guilherme, Raquel, Gomes, Marília, Ribeiro, Maria Leticia
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction: The prognostic value of interim FDG-PET/CT (iPET) in classic Hodgkin lymphoma (cHL) was demonstrated in several clinical trials. Although in last decade the PET/CT has been cHL gold standard for the staging at diagnosis and final response evaluation, the introduction of an early interim evaluation in the management algorithms and guidelines is very recent. Therefore, there are few results concerning iPET prognosis significance in real-life setting. We aimed to evaluate iPET predictor value in real-life cHL patients. Methods: A single center retrospective study was performed on cHL patients diagnosed in 2005 to 2017, who underwent iPET after two cycles of quimiotherapy. Negative iPET (iPET-) was defined as a Deauville score≤3 (Lugano classification). We did not perform any adjustment in the treatment based on iPET, except when a disease progression was evident. A p-value
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2019-131413